Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model.

Pharmacotherapy - 1 Feb 2023

Jang Ji-Hun, Jeong Seung-Hyun, Lee Yong-Bok

Abstract excerpt

BACKGROUND: Meloxicam, used for treating inflammatory diseases, shows large differences in metabolism according to CYP2C9 genetic polymorphisms; however, there are few studies on dose regimen setting based on quantitative predictions. OBJECTIVE: The aim of this study was to determine the appropriate meloxicam dose regimen for each genotype through population pharmacokinetic-pharmacodynamic modeling of meloxicam...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 36601711
DOI: 10.1002/phar.2762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model.PMID 36601711Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.Semantic proximity Read ↗

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.Semantic proximity Read ↗

Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.Semantic proximity Read ↗

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.Semantic proximity Read ↗

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.Semantic proximity Read ↗

A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Genotypes under Different Cotreatments.Semantic proximity Read ↗

Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.Semantic proximity Read ↗

Population pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infectionsSemantic proximity Read ↗

Pharmacogenomic Study—A Pilot Study of the Effect of Pharmacogenomic Phenotypes on the Adequate Dosing of Verapamil for Migraine PreventionSemantic proximity Read ↗

Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.